How Clear.bio Uses Gemini to Boost Partner Conversion by 30%
Clear.bio is a Netherlands-based health-tech startup of fewer than 50 people offering a 12-week digital intervention to reverse Type 2 Diabetes through personalized nutrition. The company deployed Google Gemini and BigQuery to build a predictive scoring model that identifies high-potential healthcare partner practices. The AI-powered system achieved 92–94% prediction accuracy, increased high-value partner conversion by 30%, and reduced outreach time by approximately 20%.
Impact
30%
Conversion rate lift
~20%
Outreach time reduction
92–94%
AI model accuracy
69%
Clinical outcome
Challenge
Clear.bio sales team was manually researching thousands of healthcare practices across the Netherlands, Germany, and France to identify high-potential partners for their diabetes reversal program, making rapid geographic expansion impossible.
Solution
The company used Google Gemini to analyze practice profiles and BigQuery to process training data, deploying an AutoML predictive scoring model via the Gemini Enterprise Agent Platform with Cloud Run functions automating the full pipeline.
Tools & Technologies
What Leaders Say
“The collaborative effort, involving engineering, product, scientific, marketing, and partner management teams, transformed a manual process into an automated, AI-powered system that streamlines how we find and prioritize the right practices. It saves our team time, reduces guesswork, and helps us reach out to the most promising practices more efficiently.”
“Our main plans are to scale the successful predictive model to more teams, get more clients, and expand to new countries. We are excited that the model has already shown great results over the last six months and is helping us reach our mission faster.”
Sign up to read complete case studies, access detailed metrics, and unlock all use cases.
Full Story
Clear.bio entered the European digital health market with a clinically validated program that uses continuous glucose monitoring data to help patients reverse Type 2 Diabetes without medication. As the company expanded from the Netherlands into Germany and France, the core business challenge shifted from product validation to distribution: how to efficiently identify and prioritize the general practices and healthcare organizations most likely to refer patients and adopt the program.
The manual approach to partner identification was a significant bottleneck. Sales staff had to individually research thousands of healthcare practices, assessing their technology adoption patterns, patient demographics, and treatment philosophies—a process that was time-consuming, inconsistent, and unable to scale alongside geographic expansion. Without a systematic way to rank prospects, the team spent equal time on low-probability and high-probability targets.
Through a Google for Startups AI Sprint program, Clear.bio cross-functional teams of engineers, product managers, scientists, and marketers designed an automated pipeline. Google Gemini analyzed healthcare practice profiles across multiple dimensions, while BigQuery served as the data warehouse for loading and preprocessing the training data. The Gemini Enterprise Agent Platform was used to train and deploy the AutoML predictive scoring model, and Cloud Run functions automated the end-to-end pipeline, triggering on new data uploads without manual intervention.
The system now assigns each practice a Best_Class score based on Gemini analysis, achieving 92–94% prediction accuracy. Sales representatives can focus their outreach on the top 20% of practices identified by the model, resulting in a 30% lift in high-value partner conversion and approximately 20% reduction in outreach time. The AI-generated insights also allow account managers to deliver highly personalized information in initial outreach, increasing engagement and contract close rates.
Beyond the partner acquisition workflow, the success of the Gemini-powered model has accelerated Clear.bio broader AI strategy. The company plans to scale the predictive model across additional teams and new geographies, using the proven six-month track record as the foundation for ongoing expansion. The same data infrastructure underpins Clear.bio patient-facing product, where personalized glucose response data guides individual nutritional recommendations—demonstrating how a unified AI platform can simultaneously optimize business operations and clinical outcomes.